Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00

АШУҮИС — Судалгааны мэдээлэл (CRIS)

Permanent URI for this communityhttps://library.mnums.edu.mn/handle/123456789/5001

Browse

Search Results

Now showing 1 - 4 of 4
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Global multi-societies endorsement of the MAFLD definition
    (2024)
    Alboraie, Mohamed
    ;
    Tanwandee, Tawesak
    ;
    Xu, Xiaoyuan
    ;
    Nikolova, Dafina
    ;
    Estupiñan, Enrique Carrera
    Scopus© Citations 4
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia.
    (2025-02)
    Choudhury, Ashok
    ;
    Kulkarni, Anand V
    ;
    Arora, Vinod
    ;
    Soin, A S
    ;
    Dokmeci, Abdul Kadir
    Scopus© Citations 103
  • Some of the metrics are blocked by your 
    Item type:Publication,
    The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
    (2025-04)
    Eslam, Mohammed
    ;
    Fan, Jian-Gao
    ;
    Yu, Ming-Lung
    ;
    Wong, Vincent Wai-Sun
    ;
    Cua, Ian Homer
    Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association for the Study of the Liver (APASL) has created clinical practice guidelines focused on MAFLD. The guidelines cover various aspects of the disease, such as its epidemiology, diagnosis, screening, assessment, and treatment. The guidelines aim to advance clinical practice, knowledge, and research on MAFLD, particularly in special groups. The guidelines are designed to advance clinical practice, to provide evidence-based recommendations to assist healthcare stakeholders in decision-making and to improve patient care and disease awareness. The guidelines take into account the burden of clinical management for the healthcare sector.
    Scopus© Citations 210
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
    (Springer Science and Business Media LLC, 2020-09)
    Sarin, Shiv Kumar
    ;
    Choudhury, Ashok
    ;
    Lau, George K
    ;
    Zheng, Ming-Hua
    ;
    Ji, Dong
    BACKGROUND AND AIMS: COVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon comorbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or without cirrhosis. METHODS: Data was collected from 13 Asian countries on patients with CLD, known or newly diagnosed, with confirmed COVID-19. RESULTS: Altogether, 228 patients [185 CLD without cirrhosis and 43 with cirrhosis] were enrolled, with comorbidities in nearly 80%. Metabolism associated fatty liver disease (113, 61%) and viral etiology (26, 60%) were common. In CLD without cirrhosis, diabetes [57.7% vs 39.7%, OR = 2.1 (1.1-3.7), p = 0.01] and in cirrhotics, obesity, [64.3% vs. 17.2%, OR = 8.1 (1.9-38.8), p = 0.002] predisposed more to liver injury than those without these. Forty three percent of CLD without cirrhosis presented as acute liver injury and 20% cirrhotics presented with either acute-on-chronic liver failure [5 (11.6%)] or acute decompensation [4 (9%)]. Liver related complications increased (p < 0.05) with stage of liver disease; a Child-Turcotte Pugh score of 9 or more at presentation predicted high mortality [AUROC 0.94, HR = 19.2 (95 CI 2.3-163.3), p < 0.001, sensitivity 85.7% and specificity 94.4%). In decompensated cirrhotics, the liver injury was progressive in 57% patients, with 43% mortality. Rising bilirubin and AST/ALT ratio predicted mortality among cirrhosis patients. CONCLUSIONS: SARS-Cov-2 infection causes significant liver injury in CLD patients, decompensating one fifth of cirrhosis, and worsening the clinical status of the already decompensated. The CLD patients with diabetes and obesity are more vulnerable and should be closely monitored.
    Scopus© Citations 227